Comparative Analysis of the Cost of Thalassemia Screening Vs Treatment in Different Healthcare Sectors in Delhi National Capital Region
DOI:
https://doi.org/10.37506/beprt342Keywords:
Thalassemia screening, cost analysis, single gene disorderAbstract
Background: Thalassemia is a single gene disorder that is passed on from parents to children. According to the World Health Organization, the carrier rate of thalassemia in is between 3- 5%. Treatment and management of a thalassemia major patient costs the family around USD 5389-13474 per year (INR 100,000–250,000) depending on the age and presence of complications. Screening of antenatal women have the potential to reduce the burden of thalassemia and could offer a much effective strategy. Methods: A hospital based cross-sectional study was conducted to assess the cost of treatment and screening. Patients visiting thalassemia treatment centres in the National Capital Region were asked questions to assess the annual cost of treatment incurred. Results: The annual treatment of thalassemia patients in government, non-governmental/charitable and private sector hospitals is being reported here. When analyzing the cost for the population at large, screening costs only 0.01% of the treatment cost. Conclusion: Therefore, we can infer that screening in whole population is much more efficacious as compared to treatment in 10,000 people. Thus, screening and prevention not only reduces the morbidity and mortality associated with the disease, but also is a better public health model for countries with high prevalence of thalassemia.
References
Verma IC, Choudhry VP, Jain PK. Prevention of thalassemia: A necessity in India. Indian J Pediatr. 1992 Nov 1;59(6):649–54.
Ansari SH, Shamsi TS, Ashraf M, Farzana T, Bohray M, Perveen K, et al. Molecular epidemiology of β-thalassemia in Pakistan: Far reaching implications. Indian J Hum Genet. 2012;18(2):193–7.
Fucharoen S, Winichagoon P. Haemoglobinopathies in Southeast Asia. Indian J Med Res. 2011 Oct;134(4):498–506.
Kantharaj A, Chandrashekar S. Coping with the burden of thalassemia: Aiming for a thalassemia free world. Glob J Transfus Med 2018;3:1-5.
Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008 Jun;86(6):480-7.
Thiyagarajan A, Bhattacharya S, Sharma N, Srivastava A, Dhar DK. Need for a universal thalassemia screening programme in India? A public health perspective. J Family Med Prim Care. 2019 May;8(5):1528–32.
Colah R, Italia K, Gorakshakar A. Burden of thalassemia in India: The road map for control. Pediatric Hematology Oncology Journal. 2017 Dec 1;2(4):79–84.
Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008 Jun;86(6):480–7.
Madan N, Sharma S, Sood SK, Colah R, Bhatia LHM. Frequency of β-thalassemia trait and other hemoglobinopathies in northern and western India. Indian J Hum Genet. 2010 Jan;16(1):16–25.
Eleftheriou A, Antoniou E, Darbà J, Ascanio M, Angastiniotis M, Farmakis D. Estimating the Cost of Thalassemia Care across the World: A Thalassemia International Federation Model. Hemoglobin. 2022 Nov;46(6):308-311.
CCEMG - EPPI-Centre Cost Converter v.1.4 [Internet]. [cited 2020 Apr 25]. Available from: https://eppi.ioe.ac.uk/costconversion/default.aspx
Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, editors. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) [Internet]. 3rd ed. Nicosia (CY): Thalassaemia International Federation; 2014. PMID: 25610943.13. Kohne E. Hemoglobinopathies. Dtsch Arztebl Int. 2011 Aug;108(31–32):532–40.
Ansari-Moghaddam A, Adineh HA, Zareban I, Mohammadi M, Maghsoodlu M. The survival rate of patients with beta-thalassemia major and intermedia and its trends in recent years in Iran. Epidemiol Health. 2018;40:e2018048.
Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for Beta-thalassaemia: a review of international practice. Eur J Hum Genet. 2010 Oct;18(10):1077–83.
Ahmadnezhad E, Sepehrvand N, Jahani FF, Hatami S, Kargar C, Mirmohammadkhani M, et al. Evaluation and Cost Analysis of National Health Policy of Thalassaemia Screening in West-Azerbaijan Province of Iran. Int J Prev Med. 2012 Oct;3(10):687–92.
National Family Health Survey (NFHS-4), 2015-16 [Internet] Dec 2017. Available from http://rchiips.org/nfhs/NFHS-4Reports/India.pdf on 15 July 2023
Dolai TK, Dutta S, Bhattacharyya M, Ghosh MK. Prevalence of hemoglobinopathies in rural Bengal, India. Hemoglobin. 2012;36(1):57–63.
Koren A, Profeta L, Zalman L, Palmor H, Levin C, Zamir RB, Shalev S, Blondheim O. Prevention of β Thalassemia in Northern Israel - a Cost-Benefit Analysis. Mediterr J Hematol Infect Dis. 2014 Feb 17;6(1):e2014012.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ritu Gupta, Nita Radhakrishnan, Ravi Shankar, Shomik Ray
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.